Bristol Myers Squibb outraces the pack to a late-stage trial win for its LAG-3/PD-1 antibody combo in melanoma
As one of biopharma’s many shots on goal at new checkpoint inhibitors, the LAG-3 class has, pun intended, lagged behind with little meaningful data to show. But a number of big drugmakers have reason to believe that a LAG-3 and PD-1 combo could solve the puzzle in oncology — and new data from Bristol Myers Squibb help that case.
A combination of antibody relatlimab and PD-1 inhibitor Opdivo significantly extended progression-free survival over Opdivo alone in first-line melanoma patients whose tumors are either metastatic or unable to be surgically removed, according to topline data from the Phase III RELATIVITY-047 study released Thursday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,800+ biopharma pros reading Endpoints daily — and it's free.